Oramed Pharmaceuticals, Inc. (ORMP) Drug News Sparks Profit-Taking in the Options Pits

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) surged higher out of the gate following upbeat data on its insulin drug, sparking possible profit-taking among call option traders

May 18, 2016 at 10:34 AM
facebook X logo linkedin

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) stock popped more than 16% out of the gate, and briefly traded above recent resistance at the round-number $10 level, following highly anticipated news on the company's oral insulin drug, ORMD-0801. The pharmaceutical firm announced this morning that the treatment met goals in a Phase II trial in patients with type 2 diabetes, and must now move on to a Phase III trial before being submitted for approval. However, the drug data -- expected to be potentially "transformative" -- may have already been priced in to ORMP shares, which have erased their gains to sit 1.1% lower at $8.93, and it looks like call options holders may have cashed out just in time.

As of yesterday, call open interest on ORMP was at an annual high. Most of the calls resided at the overhead May 10 strike. Today, ORMP calls are trading at 60 times the average intraday pace, and it looks like possible sell-to-close action occurred at the May 10 call within the first few minutes of trading, when the stock was briefly in double-digit territory -- and within a chip-shot of new annual highs.

However, bearish bets have picked up steam on Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), with put volume hitting an annual high yesterday. The stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio shows 1.63 puts bought to open for each call during the past two weeks, to be precise. Plus, while the stock is currently seated on the short-sale restricted list, short interest account for more than two weeks' worth of trading, at ORMP's average daily volume. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI